BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 16823703)

  • 1. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pyoderma gangrenosum--a less well known ulcerous skin disease].
    Kostiainen M; Snellman E; Vaalasti A; Rantanen T; Reunala T
    Duodecim; 2002; 118(10):1033-7. PubMed ID: 12237998
    [No Abstract]   [Full Text] [Related]  

  • 4. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
    Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
    Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of infliximab in pyoderma gangrenosum.
    Hewitt D; Tait C
    Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
    Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
    Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
    Swale VJ; Saha M; Kapur N; Hoffbrand AV; Rustin MH
    Clin Exp Dermatol; 2005 Mar; 30(2):134-6. PubMed ID: 15725238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
    Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
    Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
    Stichweh DS; Punaro M; Pascual V
    Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis.
    Fernández A; Velasco A; Prieto V; Canueto J; Alvarez A; Rodríguez A
    Am J Gastroenterol; 2008 Nov; 103(11):2951-2. PubMed ID: 19032482
    [No Abstract]   [Full Text] [Related]  

  • 11. [Infliximab treatment of peristomal pyoderma gangrenosum in ulcerative colitis].
    Nybaek H; Jemec GB
    Ugeskr Laeger; 2005 Aug; 167(32):2920-1. PubMed ID: 16109221
    [No Abstract]   [Full Text] [Related]  

  • 12. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.
    Brooklyn TN; Dunnill MG; Shetty A; Bowden JJ; Williams JD; Griffiths CE; Forbes A; Greenwood R; Probert CS
    Gut; 2006 Apr; 55(4):505-9. PubMed ID: 16188920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with infliximab of peristomal pyoderma gangrenosum in ulcerative colitis].
    Krag AA; Gjersøe P
    Ugeskr Laeger; 2005 May; 167(18):1968-9. PubMed ID: 15929274
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of peristomal pyoderma gangrenosum.
    Kiran RP; O'Brien-Ermlich B; Achkar JP; Fazio VW; Delaney CP
    Dis Colon Rectum; 2005 Jul; 48(7):1397-403. PubMed ID: 15868233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Septic shock after treatment of pyoderma gangrenosum with infliximab.
    Wölbing F; Fierlbeck G; Hötzenecker W; Schaller M; Röcken M
    Acta Derm Venereol; 2009; 89(1):93-4. PubMed ID: 19197554
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
    Cocco A; Angelucci E; Viscido A; Caprilli R
    Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
    Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
    Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six patients with pyoderma gangrenosum successfully treated with infliximab.
    Mooij JE; van Rappard DC; Mekkes JR
    Int J Dermatol; 2013 Nov; 52(11):1418-20. PubMed ID: 22512250
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe recalcitrant pyoderma gangrenosum treated with infliximab.
    Kaur MR; Lewis HM
    Br J Dermatol; 2005 Sep; 153(3):689-91. PubMed ID: 16120178
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of recalcitrant pyoderma gangrenosum with infliximab complicated by tuberculosis despite negative screening tests.
    Uthman I; El-Sayad J; Sharara A
    Clin Exp Dermatol; 2005 May; 30(3):294. PubMed ID: 15807693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.